Search

Your search keyword '"Gödel, P."' showing total 10 results
Start Over Author "Gödel, P." Journal blood
10 results on '"Gödel, P."'

1. Characterization and T-Cell Repertoire of MB-CART2019.1 (Zamtocabtagene autoleucel) - Data from the Phase I Trial in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Author

Holzer, Tatjana, Biedermann, Stefanie, Herfort, Inga, Friedrichs, Birte, Holtkamp, Silke, Hanssens, Linda, Assenmacher, Mario, Bethke, Ulf, Schneider, Dina, Miltenyi, Stefan, Overstijns, Toon, Schmid, Christoph, Ayuk, Francis A., Scheid, Christoph, Jühling, Anja, Holtick, Udo, Gödel, Philipp, Borchmann, Peter, and Bürger, Iris

Published
2022
Full Text
View/download PDF

2. Inferior Outcomes of EU Vs. US Patients with Relapsed/Refractory Large B-Cell Lymphoma after CD19 CAR T-Cell Therapy Are Associated with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization and CAR-T Product Selection

Author

Buecklein, Veit L, Perez-Perez, Ariel, Rejeski, Kai, Iacoboni, Gloria, Jurinovic, Vindi, Holtick, Udo, Penack, Olaf, Kharboutli, Soraya, Blumenberg, Viktoria, Ackermann, Josephine, Frölich, Lisa, Johnson, Grace, Patel, Kedar, Arciola, Brian, Schmidt, Christian, Albanyan, Omar, Gödel, Philipp, Hoster, Eva, Bullinger, Lars, Mackensen, Andreas, Locke, Frederick L., von Bergwelt, Michael, Barba, Pere, Jain, Michael D., and Subklewe, Marion

Published
2022
Full Text
View/download PDF

5. Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA

Author

Heger, Jan-Michel, Mattlener, Julia, Schneider, Jessica, Gödel, Philipp, Sieg, Noëlle, Ullrich, Fabian, Lewis, Richard, Bucaciuc-Mracica, Teodora, Schwarz, Roland F., Rueß, Daniel, Ruge, Maximilian I., Montesinos-Rongen, Manuel, Deckert, Martina, Blau, Tobias, Kutsch, Nadine, Balke-Want, Hyatt, Weiss, Jonathan, Becker, Kerstin, Reinhardt, H. Christian, Hallek, Michael, Borchmann, Peter, von Tresckow, Bastian, and Borchmann, Sven

Abstract

•Tumor-agnostic ctDNA sequencing in CNSL is feasible and allows for detection of PRD.•We propose the molecular prognostic index for CNSL, a model integrating clinical and molecular features for improved risk profiling in CNSL.

Published
2023
Full Text
View/download PDF

7. Phase I Trial of MB-CART2019.1, a Novel CD20 and CD19 Targeting Tandem Chimeric Antigen Receptor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Author

Borchmann, Peter, Jühling, Anja, Gödel, Philipp, Balke-Want, Hyatt, Schmid, Christoph, Ayuk, Francis A., Holtkamp, Silke, Preussner, Liane, Zadoyan, Gregor, Hanssens, Linda, Kaiser, Andrew, Jurk, Marion, Bürger, Iris, Schneider, Dina, Dropulic, Boro, Overstijns, Toon, Scheid, Christof, Holtick, Udo, Miltenyi, Stefan, and Hallek, Michael

Abstract

Borchmann: Miltenyi Biotec B.V. & Co. KG: Honoraria. Balke-Want:Miltenyi Biotec B.V. & Co. KG: Honoraria. Ayuk:Celgene: Consultancy, Honoraria; Kite/Gilead: Honoraria; Therakos/Mallinckrodt: Honoraria, Research Funding; Neovii: Research Funding; Novartis: Honoraria. Holtkamp:Miltenyi Biomedicine GmbH: Current Employment. Preussner:Miltenyi Biomedicine GmbH: Ended employment in the past 24 months. Zadoyan:Miltenyi Biomedicine GmbH: Current Employment. Hanssens:Miltenyi Biomedicine GmbH: Current Employment. Kaiser:Miltenyi Biotec B.V. & Co. KG: Current Employment. Jurk:Miltenyi Biotec B.V. & Co. KG: Current Employment. Bürger:Miltenyi Biotec B.V. & Co. KG: Current Employment. Schneider:Lentigen Technology Inc., A Miltenyi Company: Current Employment, Patents & Royalties. Dropulic:Lentigen Technology Inc., A Miltenyi Company: Current Employment. Overstijns:Miltenyi Biomedicine GmbH: Current Employment, Membership on an entity's Board of Directors or advisory committees; Miltenyi Biotec B.V. & Co. KG: Current Employment, Membership on an entity's Board of Directors or advisory committees. Scheid:Novartis: Honoraria, Research Funding; Janssen: Honoraria, Research Funding; BMS: Honoraria; Amgen: Honoraria; Takeda: Honoraria, Research Funding. Holtick:Miltenyi Biotec B.V. & Co. KG: Honoraria. Miltenyi:Miltenyi Biomedicine GmbH: Current Employment, Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties; Lentigen Technology Inc., A Miltenyi Company: Current Employment, Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties; Miltenyi Biotec B.V. & Co. KG: Current Employment, Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties.

Published
2020
Full Text
View/download PDF

10. Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA.

Author

Heger JM, Mattlener J, Schneider J, Gödel P, Sieg N, Ullrich F, Lewis R, Bucaciuc-Mracica T, Schwarz RF, Rueß D, Ruge MI, Montesinos-Rongen M, Deckert M, Blau T, Kutsch N, Balke-Want H, Weiss J, Becker K, Reinhardt HC, Hallek M, Borchmann P, von Tresckow B, and Borchmann S

Subjects
Humans, Neoplasm Recurrence, Local, Prognosis, Biomarkers, Tumor genetics, Central Nervous System, Circulating Tumor DNA genetics, Central Nervous System Neoplasms diagnosis, Central Nervous System Neoplasms genetics, Central Nervous System Neoplasms therapy, Lymphoma, Non-Hodgkin
Abstract

Abstract: State-of-the-art response assessment of central nervous system lymphoma (CNSL) by magnetic resonance imaging is challenging and an insufficient predictor of treatment outcomes. Accordingly, the development of novel risk stratification strategies in CNSL is a high unmet medical need. We applied ultrasensitive circulating tumor DNA (ctDNA) sequencing to 146 plasma and cerebrospinal fluid (CSF) samples from 67 patients, aiming to develop an entirely noninvasive dynamic risk model considering clinical and molecular features of CNSL. Our ultrasensitive method allowed for the detection of CNSL-derived mutations in plasma ctDNA with high concordance to CSF and tumor tissue. Undetectable plasma ctDNA at baseline was associated with favorable outcomes. We tracked tumor-specific mutations in plasma-derived ctDNA over time and developed a novel CNSL biomarker based on this information: peripheral residual disease (PRD). Persistence of PRD after treatment was highly predictive of relapse. Integrating established baseline clinical risk factors with assessment of radiographic response and PRD during treatment resulted in the development and independent validation of a novel tool for risk stratification: molecular prognostic index for CNSL (MOP-C). MOP-C proved to be highly predictive of outcomes in patients with CNSL (failure-free survival hazard ratio per risk group of 6.60; 95% confidence interval, 3.12-13.97; P < .0001) and is publicly available at www.mop-c.com. Our results highlight the role of ctDNA sequencing in CNSL. MOP-C has the potential to improve the current standard of clinical risk stratification and radiographic response assessment in patients with CNSL, ultimately paving the way toward individualized treatment., (© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results